Using new specific and sensitive enzyme-linked immunosorbent assays for inhibin A and inhibin B, we measured these proteins in amniotic fluid (AF), maternal serum (MS), and umbilical cord serum in normal pregnancies.
(14 -16 weeks gestation) there was no correlation of inhibin A levels in AF with those in MS (r ϭ 0.19; P Ͼ 0.05). In 45 term umbilical cord serum samples, no dimeric inhibin was detectable in serum from female babies, but inhibin B was detectable in male sera; the median (10 -90th percentile) concentration was 167.4 (111.2-224.8) pg/mL.
These data suggest that for the gestation periods studied, although the placenta secretes inhibin A, another source, probably the fetal membranes, secretes both inhibin A and inhibin B. Further, the presence of inhibin B in male fetuses is consistent with a testicular origin, suggesting that inhibin B may be important in the development of the fetal hypothalamo-pituitary-testicular axis. (J Clin Endocrinol Metab 82: 218 -222, 1997) I NHIBINS ARE glycoproteins that belong to the transforming growth factor-␤ superfamily (1) and are characterized by their ability to suppress FSH secretion (2) . They are composed of an ␣-subunit and one of two ␤-subunits, ␤ A or ␤ B , giving rise to two mature 32-kDa inhibins: inhibin A (␣-␤ A ) and inhibin B (␣-␤ B ) (2) . Although inhibins were originally identified from gonadal tissue, messenger ribonucleic acids (mRNAs) for the inhibin subunits are expressed in many nongonadal sites (3) , including the placenta (4). Indeed, very high circulating levels of inhibin have been reported during pregnancy, significantly higher than those in nonpregnant subjects (5) (6) (7) (8) , which then rapidly decline after delivery (6, 8, 9) . Current evidence derived from clinical studies (4 -11) , from the localization of inhibin subunit mRNA (4, 12) and proteins (4, 13) , and from trophoblast cell culture experiments (12) suggests that the placenta is probably the principal source of inhibin during pregnancy (14) .
Until recently, the available assays for inhibin were unable to differentiate between dimeric forms and partially processed free ␣-subunits or between dimers (15) (16) (17) . Thus, our current understanding of inhibins in pregnancy is largely based upon these nondiscriminatory immunoreative inhibin assays (14) . However, the development of sensitive and specific enzyme-linked immunosorbent assays (ELISAs) for inhibin A (18) and inhibin B (19) and their subsequent application have offered novel and important insights into inhibin biology in chromosomally abnormal pregnancies (20 -22) . To gain further insight into the biology of inhibin in normal pregnancy, therefore, we measured inhibin A and inhibin B in different pregnancy compartments.
Materials and Methods Samples
Amniotic fluid (AF). Aliquots of AF were obtained from the regional cytogenetics laboratory in Edinburgh, Scotland. These had been collected prospectively as part of a clinical amniocentesis service. AF was separated from fetal epithelial squamous cells by centrifugation at 250 ϫ g within 24 h of collection, and an aliquot of each sample was stored specifically for this study at Ϫ20 C until assay. The karyotype from each sample was reported subsequently.
Maternal serum (MS).
Blood samples were collected prospectively as part of the West of Scotland Down's Syndrome and Neural Tube Defects Prenatal Screening Program and from an ongoing first trimester study of serum markers. Each sample was centrifuged, and the serum was separated within 3 days of collection and stored at Ϫ20 C. Information from early pregnancy karyotyping, where performed, and birth records, where karyotyping is not performed, is routinely used to identify chromosomally abnormal babies. Through the exclusion of these, sera from chromosomally normal pregnancies were identified and retrieved from storage. To gain sex details from this normal group, a cohort of case records was retrieved and analyzed.
Matched MS and AF. In 47 women venepuncture was performed, with informed consent, immediately before amniocentesis (14 -16 weeks gestation). The blood was centrifuged, and the serum was separated on the day of collection and stored at Ϫ20 C until assay. The AF was processed as detailed above. In each case, a normal karyotype was subsequently reported.
Umbilical cord serum. In 45 normal pregnancies, at term (37-41 weeks) and in normal spontaneous labor, umbilical blood (arterial and venous) was collected after consent was obtained. After the delivery of each baby, the cord was double clamped, and blood was taken after delivery of the placenta. Blood was centrifuged on the day of collection, and serum was separated and stored at Ϫ20 C until assay.
For each sample, AF, MS, or umbilical cord serum, the time of gestation at sampling, in completed weeks, was calculated from certain menstrual dates or from an early pregnancy ultrasound scan. Ethical approval was granted by the Lothian research ethics committee.
Assays
Inhibin A. Inhibin A was measured using a two-site ELISA (18) that has been previously validated for human serum (23) but with some modifications. Before assay, samples (and standards) underwent two preparatory steps. Each was mixed with 2% (final wt/vol) SDS and heated in a water bath at 100 C for 3 min. After cooling, each sample or standard was mixed with 1% (final wt/vol) hydrogen peroxide, incubated at room temperature for 30 min, and then diluted 1:1 in assay diluent (0.1 mol/L Tris-HCl, 0.15 mol/L NaCl with 5% Triton X-100, 10% BSA, and 5% normal mouse serum, pH 7.5). The assay uses an immobilized anti-␤A-inhibin subunit monoclonal antibody (E4) as a capture antibody, covalently coupled to hydrazide microplates (Avidplate-HZ, UniSyn Technologies, Tustin, CA). The Fab fraction of a mouse anti-␣-inhibin subunit monoclonal antibody (R1) is used as a second antibody diluted in assay diluent. This is conjugated to alkaline phosphatase, allowing detection by the addition of an alkaline phosphatase substrate, p-nitrophenylphosphate (Kirkegaard and Perry Laboratories, Gaithersburg, MD). Inhibin, immunopurified from follicular fluid and calibrated against recombinant 32-kDa human inhibin A (Genentech, South San Francisco, CA), was used as a standard preparation. Plates were read at 405 nm in a microplate reader (Thermomax, Molecular Devices Corp., Menlo Park, CA) using dedicated software (Softmax, Molecular Devices Corp.). Results are expressed as picograms per mL, with an assay sensitivity of 23 pg/mL. The intra-and interplate coefficients of variation were 4.3% and 5.6%, respectively. The cross-reactivity of this assay with activin A, activin B, follistatin, purified human pro-␣C, and inhibin B is less than 0.1%. The recovery of recombinant human inhibin A spiked into AF was quantitative (mean Ϯ sem, 108 Ϯ 13%; n ϭ 10). Serial dilution of AF samples gave dose responses parallel to that of the immunopurified standard (Fig. 1) .
Inhibin B. Inhibin B was measured using a similar two-site ELISA as previously described (19) . A monoclonal antibody (C5) raised against the human inhibin ␤ B -subunit was used as a capture antibody, biotinylated, and immobilized on streptavidin-coated microplates (Life Sciences International, Basingstoke, UK). The same second antibody (R1) as that used in the inhibin A assay was employed. Samples and standards were also pretreated as detailed above, but in this assay the signal was detected using an alkaline phosphatase amplification kit (Life Technologies, Paisley, UK). The same immunopurified inhibin preparation as that detailed above was used as a standard but calibrated against recombinant human inhibin B, with results expressed in picograms per mL. Plates were read at 490 nm using the same apparatus and software as those described for the inhibin A assay. The assay detection limit was less than 5 pg/mL. Activin A, activin B, follistatin, and purified human pro-␣C had less than 0.1% cross-reaction, whereas recombinant inhibin A had 0.5% cross-reaction. The intra-and interplate coefficients of variation were 7.6% and 8.1%, respectively. Recovery of recombinant human inhibin A spiked into AF was quantitative (mean Ϯ sem, 88 Ϯ 11%; n ϭ 8). Serial dilution of AF gave a dose response parallel to that of the immunopurified standard (Fig. 1) .
Statistical analyses were performed using Statview 4.1 (Abacus, Berkeley, CA) and SPSS for Windows (SPSS, Chicago, IL). Regressed medians were calculated to compare the ontogeny of the inhibins in each compartment, and multiples of the median (MoM) were used to correct for gestational changes, allowing group comparisons across gestations.
The regression equations calculated were: AF inhibin A: median ϭ e (11.3209 -84 Results AF AF samples from 618 consecutive amniocenteses were available for measurement of inhibin A content. In 15 (2.4%), karyotyping was abnormal, and these were excluded from this study. Of the 603 AF samples analyzed, 388 (64.3%) were unselected with regard to placental function [tests were performed for reasons of maternal age (n ϭ 350), maternal anxiety (n ϭ 19), or past history (n ϭ 19)] and were grouped together (group A). The remaining 215 (35.7%) amniocenteses (group B) had been performed after an abnormal ultrasound scan (n ϭ 15) or after positive MS screening, based on maternal age and MS levels of intact hCG and alphafetoprotein, had indicated an increased risk of fetal trisomy 21 (n ϭ 200).
Inhibin A levels were analyzed for groups A and B separately by completed week of gestation and by fetal sex. There were no significant differences in inhibin A levels between the two groups (P Ͼ 0.05, by Mann-Whitney U test; data not shown) or between sexes in either group A or B (P Ͼ 0.05, by Mann-Whitney U test; data not shown). Data from all AF samples were, therefore, combined regardless of in- dication for sampling or fetal sex and analyzed by gestational age. Table 1 details the median and 10th and 90th percentiles for inhibin A in AF in these 603 pregnancies. Levels increased steadily across the gestational window of 14 -20 weeks, as evidenced by the regressed medians (Fig. 2) .
Inhibin B assays were performed on 189 of the 603 AF samples. Where possible (weeks 14 -18 inclusive), all samples were from group A, with 15 samples for each sex at each gestation. At 19 and 20 weeks, however, there were insufficient numbers in group A alone, and 7 samples at each gestation (1 female and 6 males at 19 weeks and 3 females and 4 males at 20 weeks) were derived from group B. There were no significant differences in inhibin B levels between the 23 AF samples from group A and the 7 from group B at 19 weeks gestation or between the sexes at any time of gestation (P Ͼ 0.05, by Mann-Whitney U test; data not shown). The data were, therefore, grouped by gestation, combining both sexes within each group. Table 2 details the median and 10th and 90th percentiles for inhibin B in these 189 pregnancies. Levels increased steadily across the gestational window, as shown in Fig. 2 .
There was significantly more inhibin A than inhibin B at 14 -16 weeks gestation (P Ͻ 0.001, by Mann-Whitney U test), but because the levels of inhibin B rose more rapidly, this became nonsignificant at 17 weeks (Fig. 2) . There was a significant, but weak, association between the levels of inhibin A and B in the 189 amniotic fluid samples (r ϭ 0.42; P ϭ 0.0001).
MS
Sera from 807 chromosomally normal singleton pregnancies from 10 -20 completed weeks of pregnancy were analyzed for inhibin A and inhibin B. Table 3 details the distribution of these sera by gestation and the median (10th and 90th percentiles) inhibin A levels. Levels fell significantly from 10 weeks to a nadir at 17 weeks (P Ͻ 0.0001, by MannWhitney U test), rising again to 20 weeks (P Ͻ 0.0001, by Mann-Whitney U test; Fig. 2 ).
Sexing information was available from the case records of 165 of the 807 pregnancies, 91 males and 74 females. When expressed as multiples of the median (MoM), correcting for gestation, there were no sex differences (1.02 MoM vs. 1.04 MoM for males and females, respectively; P ϭ 0.88, by MannWhitney U test).
Inhibin B was undetectable in MS.
Matched MS and AF
Inhibin A was measured in matched maternal sera, and AF samples were collected from 47 women at 14 -16 weeks gestation. The median (10 -90th percentiles) inhibin A levels in MS and AF were 123.7 (79.0 -196.1) and 802.5 (250.6 -1731.4) pg/mL, respectively; the levels in AF were significantly higher than those in MS (by paired t test, P Ͻ 0.001). Inhibin A levels in the AF and MS samples were not significantly correlated (r ϭ 0.19; P Ͼ 0.05).
Umbilical cord serum
Cord blood was obtained from 45 pregnancies at term (37-41 weeks gestation), 24 with a female baby and 21 with a male, as evident on examination. Inhibin A was undetectable in all 45 samples, both arterial and venous. Inhibin B was undetectable in the cord serum from all female babies, but was present in serum from all 21 male babies, with no differences between arterial or venous blood levels. The median (10 -90th percentile) inhibin B level in the umbilical vein was 167.4 (111.2-224.8) pg/mL. There was no association between cord inhibin B level and either gestation (r ϭ 0.005; P ϭ 0.98) or birth weight (r ϭ 0.11; P ϭ 0.6).
Discussion
Immunoreactive inhibin levels throughout pregnancy have been extensively reported using inhibin ␣-subunitbased assays (5) (6) (7) (8) (9) . Serum levels of immunoreactive inhibin rise from ovulation to a peak at 9 -10 weeks gestation, falling to a plateau at approximately 15 weeks and thereafter rising in the third trimester to another peak at term (5) (6) (7) (8) . A similar biphasic ontogeny for inhibin A has been recently described (24, 25) . On this much larger series of MS samples than previously reported, our findings confirm the biphasic profile, but show that inhibin A levels rise at 18 weeks gestation, earlier than previously reported (24) . Contrary to our findings, Qu et al. (26) showed a steady rise in bioactive inhibin levels without the biphasic profile. It would now appear that these bioactive inhibin data have been confounded by either other FSH-regulating peptides in MS, such as activin (27) , or by inadequate stripping of the very high levels of circulating sex steroids that exist in pregnancy (26) . Our studies also demonstrate that inhibin B is not detectable in MS at 10 -20 weeks gestation, extending the finding of a previous report that inhibin B was absent in MS up to 11 weeks gestation (25) . This is the first report of specific inhibin dimers in AF. The higher level of inhibin A in AF than in MS is consistent with existing reports of immunoreactive inhibin levels in these compartments (28, 29) . It is perhaps surprising that AF levels of inhibin A are higher than those in MS because hCG, which is also secreted by the placenta, is significantly lower in AF than in serum (30, 31) , consistent with secretion from the placenta into the maternal circulation. Our data suggest that either inhibin A is preferentially secreted by the placenta into the AF, rather than the maternal circulation, which is unlikely considering anatomical relationships, or that there is another significant source of inhibin during pregnancy. The lack of correlation of AF inhibin A with MS inhibin A and the differing ontogenies of inhibin A in MS and AF support the latter explanation, suggesting that different sources contribute to different compartments. Furthermore, the presence of inhibin B in AF, but not in MS, and the finding that AF levels of inhibin A and inhibin B are only weakly associated are also consistent with the presence of at least two independent sources of inhibin.
Potential sources of inhibin in pregnancy include the decidua, the fetus, and the fetal membranes, which all express inhibin subunit mRNAs (32) (33) (34) . The decidua is an unlikely candidate, as it preferentially expresses ␤ B -subunit mRNA (32) , suggesting that it would secrete more inhibin B than inhibin A, the converse of our observations. Further, if decidually derived, it might be expected that inhibins would be detectable in both MS and AF, similar to other decidual products, such as PRL and placental protein 14 (30, 35, 36) , but inhibin B is not detectable in MS. It is possible that the inhibins in AF may be fetally derived, as alphafetoprotein, which is of fetal origin, is found in higher concentrations in AF than MS (37), similar to inhibin A. Previous studies of immunoreactive inhibin in cord serum concluded that the fetus was not a significant source of inhibin (5, 6, 8) , and although we were unable to collect fetal blood at 10 -20 weeks, we demonstrated that there is no inhibin A in the fetal circulation at term, which would argue against a fetal source for the inhibin A in AF. The fetal membranes are, therefore, the likely origin of the inhibin A in AF at the gestation periods studied. Of these, the amnion selectively expresses ␤ B -subunit mRNA (34) , which is more indicative of activin production, but the chorion expresses mRNA for both the ␤ Aand ␣-subunits (34), consistent with inhibin A secretion.
The fetal membranes are also the probable source of the inhibin B detected in AF. We found no sex differences in AF inhibin B levels, which is not consistent with our umbilical cord data or previous midgestation data for immunoreactive inhibin (38) . This would argue against a significant fetal contribution to the inhibin B content of AF, although, as for inhibin A, we were unable to collect fetal blood at the earlier gestation times, and we cannot exclude the fetus as a contributor of inhibin B to AF.
In cord serum from female babies, neither inhibin A nor inhibin B was present, but in the males, we found levels of inhibin B comparable to those in adult men (39) . This differs from a previous report that no dimeric inhibins are present in cord serum (40) . That Billiar and colleagues (40) found no inhibin B can be explained by the capture antibody (E4) used in their ELISA-B assay, which is an antiinhibin ␤ A -subunit antibody displaying no significant affinity for the inhibin ␤ B -subunit. The fetal testis expresses mRNA for the inhibin subunits, whereas the ovary does not (32) , in keeping with inhibin B being of testicular origin, rather than from another source common to both sexes, such as the adrenals. Therefore, these data may be novel evidence that the human fetal testis secretes dimeric inhibin. It is likely that the majority of the inhibin detected in cord serum by the inhibin ␣-subunit assays used in previous studies (5, 6, 8) is free ␣-subunit (40) . Although there are no sex differences in immunoreactive inhibin levels in cord serum at term (6, 8, 41) , at 26 -28 weeks, immunoreactive inhibin levels are higher in males than in females (38) . In light of our data, the immunoreactive inhibin findings at earlier periods of gestation may represent relative changes in inhibin B, particularly when at these times of gestation FSH levels in males are significantly lower than those in females (38, 42, 43) . This sex difference in circulating FSH has been previously explained by the higher circulating levels of testosterone in males (42, 43) , but it is possible that it may at least in part be due to inhibin B, being evidence of negative feedback by inhibin B on fetal pituitary FSH secretion at these periods of gestation. In summary, our data offer some clarification of the biology of inhibin in early to midpregnancy, providing evidence to challenge the concept that the placenta is the only significant source of inhibin A in pregnancy. We suggest that the placenta secretes inhibin A primarily into the maternal circulation, whereas the fetal membranes are the likely major source of both inhibin A and inhibin B in AF. Our data also show for the first time that the fetal testis may secrete inhibin B.
